Phase I Study of Milatuzumab for Graft Versus Host Disease
Verified February 2015 by Immunomedics, Inc.
Ohio State University
Information provided by (Responsible Party):
First received: August 7, 2012
Last updated: February 12, 2015
Last verified: February 2015
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
GVHD (Acute or Chronic)
Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Chronic Myelogenous Leukemia (CML)
Multiple Myeloma (MM)
Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies
Primary Outcome Measures:
Secondary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||January 2016 (Final data collection date for primary outcome measure)
Milatuzumab will be added to the standard GVHD reduced intensity consitioning and prophylaxis regimen of fludarabine, busulfan, tacrolimus and low-dose methotrexate.
Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Males or non-pregnant, non-lactating females, ≥ 18 years of age
- Able to understand and willing to sign informed consent.
- Histologically confirmed hematologic malignancy that is deemed best treated by RIC allogeneic SCT, including:
- Acute myeloid or lymphoblastic leukemia (AML, ALL) with < 5% blasts in the bone marrow
- Myelodysplastic syndrome and intermediate-2 or high-risk IPSS score with < 5% blasts in the bone marrow
- Chronic myelogenous leukemia failing to respond to at least two different tyrosine kinase inhibitors
- Multiple myeloma that has relapsed following autologous stem cell transplant
- Follicular lymphoma (grades 1, 2, or 3a by WHO criteria) or monocytoid lymphoma that has relapsed following at least two prior chemotherapy regimens and with either no lymph node groups ≥ 3 cm or with a ≥ 50% reduction in estimated lymph node diameter with most recent salvage therapy
- Diffuse large B-cell NHL that has relapsed after at least 2 prior chemotherapy regimens (could include high-dose chemotherapy with autologous stem cell rescue) and is still sensitive to chemotherapy by virtue of a PR or CR following most recent salvage chemotherapy
- Transformed follicular lymphoma that has achieved a PR or CR following chemotherapy
- Mantle cell lymphoma that has relapsed after at least 2 prior chemotherapy regimens (could include high-dose chemotherapy with autologous stem cell rescue)
- CLL/SLL/PLL that meets one of the following:
- del (17p13.1) in first remission
- Response no better than a PR with chemoimmunotherapy or relapse within 2 years of chemoimmunotherapy
- Richter's transformation
- Complex karyotype
- At least 4 weeks beyond prior chemotherapy (excluding steroids), antibody therapy, radiation, or radioimmunoconjugate therapy, and with any kinase inhibitors discontinued at least one week prior to starting the conditioning regimen.
- ECOG performance status ≤ 2
- Life expectancy of greater than 3 months
- Adequate organ function measured by the following within seven days of beginning conditioning:
- AST (SGOT) ≤ 3.0 x institutional upper limit of normal (IULN)
- Total bilirubin ≤ 1.5 xIULN unless due to Gilbert's disease
- Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 50 mL/min
- DLCO > 40% with no symptomatic pulmonary disease
- LVEF by echocardiogram or MUGA of at least 30%
- Women of child bearing potential and men must agree to use contraception prior to study entry and for the duration of study participation.
- Matched (8/8) related or matched unrelated donor identified. Haploidentical or umbilical cord grafts are not allowed.
- Donor willing to donate peripheral blood stem cells and meets institutional criteria for stem cell donation.
- Prior allogeneic stem cell transplant
- Patients requiring a myeloablative conditioning regimen
- Patients best served by a bone marrow transplant are not eligible as this study will be restricted only to peripheral stem cells.
- No suitable donor identified
- Prior anaphylactic response or Grade 4 infusion reaction to milatuzumab
- Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with active hepatitis B infection are not eligible. Patients with a history of hepatitis B (surface antigen or core antibody positive) must take lamivudine or equivalent during study therapy and for one year after completion of milatuzumab.
- LVEF < 30%
- Seropositivity for HIV or Hepatitis C
- Patients with known CNS lymphoma are excluded because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- Active secondary malignancies with the exception of non-melanomatous skin cancers or low risk prostate cancer under observation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01663766
|Ohio State University Comprehensive Cancer Center
|Columbus, Ohio, United States, 43210 |
|Contact: Katie Cortright 614-688-7562 Katie.Cortright@osumc.edu |
|Principal Investigator: Samantha Jaglowski, MD |
Ohio State University
||William Wegener, MD, PhD
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 7, 2012
||February 12, 2015
||United States: Food and Drug Administration
Keywords provided by Immunomedics, Inc.:
GVHD (acute or chronic)
acute myeloid or lymphoblastic leukemia (AML or ALL)
Chronic myelogenous leukemia (CML)
Multiple Myeloma (MM)
Non-Hodgekin lymphoma (NHL-both follicular & diffuse large cell)
Chronic lymphocytic leukemia or small lymphocytic leukemia (CLL or SLL)
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on February 27, 2015
Graft vs Host Disease
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms, Plasma Cell
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Blood Protein Disorders
Bone Marrow Diseases
Immune System Diseases
Neoplasms by Histologic Type